Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.

Hulin-Curtis SL, Davies JA, Jones R, Hudson E, Hanna L, Chester JD, Parker AL.

Oncotarget. 2018 May 29;9(41):26328-26341. doi: 10.18632/oncotarget.25242. eCollection 2018 May 29.

2.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
3.

The Wales Cancer Research Centre: improving cancer care together.

Chester JD, Bond JR, Batt EA.

Ecancermedicalscience. 2017 Apr 19;11:ed65. doi: 10.3332/ecancer.2017.ed65. eCollection 2017.

4.

Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.

Hulin-Curtis SL, Uusi-Kerttula H, Jones R, Hanna L, Chester JD, Parker AL.

Cancer Gene Ther. 2016 Jul;23(7):229-34. doi: 10.1038/cgt.2016.22. Epub 2016 May 27.

5.

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL.

Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545.

6.

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL.

Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015.

7.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology.

Lancet Oncol. 2015 Jan;16(1):76-86. doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11.

PMID:
25498218
8.

Personalised cancer medicine.

Jackson SE, Chester JD.

Int J Cancer. 2015 Jul 15;137(2):262-6. doi: 10.1002/ijc.28940. Epub 2014 May 12. Review.

9.

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).

Nicholson S, Hall E, Harland SJ, Chester JD, Pickering L, Barber J, Elliott T, Thomson A, Burnett S, Cruickshank C, Carrington B, Waters R, Bahl A.

Br J Cancer. 2013 Nov 12;109(10):2554-9. doi: 10.1038/bjc.2013.620. Epub 2013 Oct 29.

10.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD.

Cancer. 2012 Aug 15;118(16):3920-7. doi: 10.1002/cncr.26675. Epub 2012 Jan 3.

11.

Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.

Harvey TJ, Hennig IM, Shnyder SD, Cooper PA, Ingram N, Hall GD, Selby PJ, Chester JD.

Cancer Gene Ther. 2011 Nov;18(11):773-84. doi: 10.1038/cgt.2011.43. Epub 2011 Aug 12.

PMID:
21836632
12.

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Naik JD, Twelves CJ, Selby PJ, Vile RG, Chester JD.

Clin Cancer Res. 2011 Jul 1;17(13):4214-24. doi: 10.1158/1078-0432.CCR-10-2848. Epub 2011 May 16.

13.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA.

Br J Cancer. 2011 Jan 4;104(1):75-82. doi: 10.1038/sj.bjc.6606016. Epub 2010 Nov 30.

14.

Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.

Harvey TJ, Burdon D, Steele L, Ingram N, Hall GD, Selby PJ, Vile RG, Cooper PA, Shnyder SD, Chester JD.

Gene Ther. 2010 Aug;17(8):1000-10. doi: 10.1038/gt.2010.45. Epub 2010 Apr 22.

15.

A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.

Seymour MT, Trigonis I, Finan PJ, Halstead F, Dunham R, Wilson G, Farrugia D, Chester JD, King J, Brown CB, Slevin ML, Joel SP.

Eur J Surg Oncol. 2008 Apr;34(4):403-9. Epub 2007 Jul 2.

PMID:
17604939
16.

High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours.

El-Helw LM, Naik JD, Chester JD, Joffe JK, Selby PJ, Coleman RE.

BJU Int. 2006 Sep;98(3):519-25.

17.

Novel urothelium specific gene expression identified by differential display reverse transcriptase-polymerase chain reaction.

Hall GD, Smith B, Weeks RJ, Selby PJ, Southgate J, Chester JD.

J Urol. 2006 Jan;175(1):337-42.

PMID:
16406938
18.

Transcriptional control of the human urothelial-specific gene, uroplakin Ia.

Hall GD, Weeks RJ, Olsburgh J, Southgate J, Knowles MA, Selby PJ, Chester JD.

Biochim Biophys Acta. 2005 Jun 30;1729(2):126-34.

PMID:
15913809
19.

Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.

Chester JD, Hall GD, Forster M, Protheroe AS.

Cancer Treat Rev. 2004 Jun;30(4):343-58. Review.

PMID:
15145509
20.

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, Davis T, Button CJ, Seymour MT.

J Clin Oncol. 2003 Mar 15;21(6):1125-32.

PMID:
12637480
21.
22.

A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.

Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT.

Br J Cancer. 2002 Aug 12;87(4):393-9.

23.

Management of lymphoma patients in a cancer unit: an audit of 15 years' experience in a district general hospital.

Chester JD, Clark CJ, Gouldesbrough DR, Bogle SM, Bradley CJ, Parker D.

Clin Oncol (R Coll Radiol). 2001;13(4):243-50.

PMID:
11554620
24.

Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.

Chester JD, Dent JT, Wilson G, Ride E, Seymour MT.

Ann Oncol. 2000 Feb;11(2):235-7.

PMID:
10761764

Supplemental Content

Loading ...
Support Center